The abstract is read at the publisher; the summary is JClub's.
Low-dose blinatumomab given as 2 cycles by continuous intravenous infusion in 2 patients (anti-Mi-2-positive dermatomyositis and refractory ANCA-associated vasculitis) showed rapid T-cell activation and B-cell depletion with clinical improvement.
- Why it matters: Autoimmune diseases like dermatomyositis and refractory ANCA-associated vasculitis lack targeted options that can be monitored with detailed immune readouts for safety and efficacy.
- What they did: Two patients received blinatumomab (CD19×CD3 bispecific T-cell engager antibody) for 2 cycles, with assessments every 2 weeks to week 12, then every 4 weeks to week 24 and again at week 56; immune dynamics used flow cytometry and single-cell RNA sequencing.
- The result: Across 14 months, both patients had clinical improvement without cytokine release syndrome or other serious adverse events, and by 12 weeks T and B cells returned toward homeostasis with reduced B-cell activation and downregulation of proinflammatory genes in myeloid compartments.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.